---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-088680"
form_type: "8-K"
ticker: "TOVX"
cik: "0000894158"
company_name: "Theriva Biologics, Inc."
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:55:36.209366+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Theriva Biologics Q2 2024 cash $16.6M, VIRAGE trial to complete enrollment in Q3

## Summary
- Cash $16.6M as of June 30, 2024 vs $23.2M at Dec 31, 2023; runway into Q2 2025.
- VIRAGE Phase 2b trial for VCN-01 in metastatic PDAC expected to complete enrollment in Q3 2024.
- FDA granted Fast Track Designation for VCN-01 in metastatic pancreatic adenocarcinoma.
- Goodwill impairment of $4.0M recorded due to stock price decline and increased discount rate.
- R&D expenses $3.0M, G&A $1.5M for Q2 2024.

## SEC filing metadata
- accession: 0001104659-24-088680
- form_type: 8-K
- ticker: TOVX
- cik: 0000894158
- company_name: Theriva Biologics, Inc.
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/894158/000110465924088680/0001104659-24-088680-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/894158/000110465924088680/tm2421314d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-088680
- JSON: https://secwatch.observer/filing/0001104659-24-088680.json
- Plain text: https://secwatch.observer/filing/0001104659-24-088680.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.